Our lawyers are reviewing Elmiron lawsuits for victims who have suffered vision loss, pigmentary maculopathy, toxic maculopathy, or other eye conditions as a result of the use of Elmiron for interstitial cystitis or bladder pain.
The purpose of this page is to provide:
- an update on the current status in June 2022 of the Elmiron lawsuits in the MDL class action and Pennsylvania and New Jersey state court
- information on eye injuries with Elmiron and the connection between this medication and macular degeneration
- what our lawyers expect for an average individual settlement amount in the Elmiron class action lawsuit
- the plan for how the Elmiron lawsuit will proceed in the MDL class action and in state court
The Elmiron MDL (In Re: Elmiron (Pentosan Polysulfate Sodium) Prod. Liab. Litigation, MDL 2973) was established in the U.S. District Court for New Jersey under Judge Brian Martinotti. Judge Martinotti is a seasoned class action judge. These eye injury and blindness claims have been proceeding in pre-trial discovery.
ELMIRON LITIGATION UPDATES:
July 4, 2022 Elmiron Lawsuit Update: We are now just six months from our first Elmiron trial in January 2023. Things are heating up.
Over the last 30 days, the Elmiron eye damage class action lawsuit has seen a major spike in the number of new case filings. Since May 16, a total of 326 new Elmiron lawsuits have been filed or transferred into the Elmiron MDL. This is the biggest monthly jump in new Elmiron lawsuits so far and it makes the Elmiron class action MDL one of the most active mass torts in the country over the last month. The total number of plaintiffs in the Elmiron MDL as of June 15 is 1,360.
The pace of Elmiron vision loss lawsuits may be slowing, however. In the last two weeks of June, however, only two new Elmiron claims have been added to the MDL-2973.
June 7, 2022 Elmiron Lawsuit Update: We now know the first Elmiron lawsuit that will go to trial in seven months. Judge Martinotti ruled last week that Maria Windham's will be the first trial in January 2023.
Windham was picked by the defense lawyers to go to trial. Usually, that means it is a strong case for the defendants. But our Elmiron lawyers believe this is a very winnable case. In this litigation, every Elmiron lawsuit can be won at trial. Our attorneys believe the Elmiron claims are very strong cases. Defense attorneys will always be drawn to a lawsuit that will be tried under Louisiana law because that state's law is not typically favorable to victims. But this Elmiron eye injury lawsuit can definately be won at trial.
June 3, 2022 Elmiron Lawsuit Update: After selecting the first three bellwether IC medication trials, the judge in the Elmiron MDL issued a new Case Management Order establishing revising scheduling deadlines for pretrial discovery and motions in the test cases
In all three Elmiron lawsuits going to trial, pre-trial discovery will conclude by September 9, 2022 and dispositive motions are due by September 20, 2022. Bellwether Elmiron trial No. 1 will be held in January 2023. Bellwether trial No. 2 will commence in March and the 3rd trial will be in May 2023.
May 10, 2022: The Elmiron class action judge recently announced his selections for the three Elmiron bellwether trial cases: Manning (21-cv-11942), Broussard (21-cv-2028), and Windham (20-cv-14670).
Julia Manning (a case picked by the plaintiffs) is a resident of Georgia who took Elmiron from 2008 to 2014 and suffered damage to both eyes. The defense team selected Opal Broussard, a Louisiana resident who claims that she used Elmiron and suffered “a loss of vision and a diagnosis of macular degeneration.”
The third plaintiff, Maria Windham, was selected by the MDL Judge, but it was also a case nominated by the defense. Windham is a 67-year-old Louisiana resident who claims that she suffered pigmentary maculopathy after taking Elmiron for just two years. In most class action lawsuits, any case picked by the defendant is likely to lead to defense verdict. But the cases in this litigation are strong enough where Elmiron lawyers think there is a chance of winning in any case that goes to trial.
May 5, 2022: Over 900 victims has joined the Elmiron lawsuit in federal court in New Jersey. This 16-month-old class action has not grown as fast as many Elmiron lawyers expected. Why? Not enough Elmiron patients and prescribing doctors are connecting Elmiron to their vision loss. In class action lawsuits, often television commercials increase awareness. But there are not enough potential claims for Elmiron attorneys to make a strong investment marketing for vision loss lawsuits on television.
This is unfortunate because many worthy plaintiffs will never know they have a claim for which they might be eligible for settlement compensation. There is, however, a flip side to this coin for patients who have brought a claim. Elmiron lawsuit settlement amounts will be higher per person in a mass tort with fewer plaintiffs. It makes it easier for the defendants to resolve the lawsuit without burdening shareholders, which pushes settlement payout higher.
April 14, 2022: The monthly status conference will be held next in the Elmiron MDL-2973. The agenda will likely include a new date for the elusive science day - it keeps getting scheduled and rescheduled - and address various other housekeeping issues related to the Elmiron class action lawsuit bellwether selection process.
April 1, 2022: At the Monthly Status Conference for March, the judge in the Elmiron class action issued another Case Management Order (CMO No.27). CMO 27 updated the status of the litigation, noting that a total of 803 Elmiron product liability lawsuits have been filed (712 in federal courts, 91 in New Jersey state courts, and an unknown number in Pennsylvania state court). The judge also agreed to reschedule the upcoming Science Day for, incredibly, the third time.
March 17, 2022: In the first week of March, the judge in the Elmiron MDL issued a series of Case Management Orders which addressed various housekeeping issues and set the table for the litigation moving forward this year. At the next monthly status conference, Judge Martinotti will finalize the protocol for how the first bellwether cases will be selected. Fact discovery on the pool of bellwether candidate cases will conclude at the end of the month. The first group of bellwether trial cases will be selected by April 8, 2022. The Elmiron “science day” was rescheduled for March 25 and a new mandatory Case & Claim Data Form (“CCDF”) was approved.
February 22, 2022: The New Jersey Supreme Court ordered that all Elmiron vision loss lawsuits pending in New Jersey state courts will be consolidated before a single judge in Bergen County. This is the New Jersey state court equivalent of an MDL. There are already over 800 Elmiron lawsuits in federal courts consolidated in the Elmiron MDL-2973.
February 1, 2022: There are now 714 Elmiron eye damage lawsuits in the MDL class action.
January 13, 2022: The next case management conference in the Elmiron class action lawsuit was held yesterday. There were no significant developments. The Science Day to educate the judge on the issues in the litigation with expert witnesses was reset for March 23, 2022.
January 7, 2022: There are now 679 Elmiron class action lawsuits, up from 622 eye damage class action lawsuits in November and 580 in October. There are another 80 Elmiron lawsuits that have been filed in state court in New Jersey and Pennsylvania. So this macular degeneration litigation continues to grow. Our Elmiron lawyers believe there will be over 1,000 vision side effects lawsuits in 2022 as awareness of the connection between Elmiron and vision side effects grows.
December 14, 2021: Judge Brian Martinotti (District of New Jersey) held a case management conference in the Elmiron MDL class action lawsuit last week. The conference addressed housekeeping issues including proposed dates for rescheduling the Elmiron “Science Day,” and logistics of document discovery from Janssen Pharmaceuticals. A process for the selection of bellwether cases has already been set. Judge Martinotti will hold monthly management conferences throughout 2022 in preparation for the opening round of test trials in January 2023.
December 5, 2021: The Judicial Panel on Multidistrict Litigation created a new MDL class action for the consolidated handling of all Elmiron lawsuits in federal courts. Three trial dates have now been set. The Elmiron litigation is proceeding, mostly with discovery against Janssen and Teva as lawyers prepare for the first bellwether trial. Judge Martinotti ordered the parties to prepare a bellwether test trial plan with the first Elmiron bellwether trial to be held in January 2023.
Yes, the trial of the first eye injury case is still 11 months away. But getting a trial date - three trial dates as we discuss below - is a big deal. Our Elmiron lawsuit attorneys' prediction - and it is just a prediction - is an Elmiron global settlement will occur before a single Elmiron lawsuit goes to trial. Our lawyers believe these are very strong cases for the plaintiffs.
November 1, 2021: Judge Martinoitti denied the defendants' lawyers' effort to amend Case Management Order #1 to file a motion to dismiss plaintiffs' Elmiron lawsuits that allege a manufacturing defect with Elmiron. The defense lawyers are correct that the focus of these lawsuits. So this motion might eventually be granted. But the court ruled that at this stage of the Elmiron class action, this motion is premature.
October 22, 2021: Judge Martinoitti was supposed to have a "Science Day" last month to allow Elmiron lawyers on both sides to educate the judge by providing an overview of the key medical and scientific issues pertinent to Elmiron and the plaintiffs' allegations of eye injuries and blindness. But Science Day was postponed to an undetermined date in the future.
October 1, 2021: Sometimes in lawsuits like these Elmiron claims, the scientific literature looks promising but turns in favor of the defendants. The medical literature in this case that is now coming out continues to support the arguments plaintiffs' Elmiron class action lawyers are making. A Northwestern University study looked at the presence of Elmiron-related maculopathy. Researchers examined the medical records of 131 Elmiron patients. Forty underwent imaging and 91 underwent fundus examinations.
August 11, 2021: A new Elmiron lawyer has been added to the steering committee. There are now 310 federal eye damage claims in federal court and 51 in New Jersey and Pennsylvania state courts.
Studies suggest that Elmiron causes retinal damage to the eyes. One study confirmed that Elmiron can cause a serious eye disease called maculopathy that can result in blindness in potentially one-fourth of the patients who took this drug.
This is a pretty staggering number, right? Our class action lawyers rarely see mass torts with a risk of injury as high as it is with Elmiron. Let's say this number is off by half. That would still be a tragic number of victims.
Anyone who used the drug Elmiron and has been diagnosed with maculopathy or other eye conditions may be entitled to financial compensation from the drug manufacturer. Our law firm is currently accepting new cases from anyone who used this prescription medication and has been diagnosed with pigmentary maculopathy, macular degeneration, or other conditions.
These lawsuits are growing quickly. The quirky thing about this litigation is that Elmiron users will often not link their vision issues to the drug. The cause of these vision loss injuries will often be misdiagnosed -- they have already been told by a doctor there was some other cause for the eye injury.
But when awareness of the side effects of Elmiron increases, the number of victims lawyers will see will increase accordingly.
Elmiron is the popular brand name of a drug called pentosan polysulfate sodium. Pentosan polysulfate belongs to a family of anticoagulant drugs known as low molecular weight herapins. Most drugs in this category are used as blood thinners, but Elmiron is used for the treatment of a condition called interstitial cystitis ("IC"). Millions of people take it every day. Janssen continues to make a fortune from this IC drug.
Interstitial cystitis is a bladder condition that causes chronic pain and discomfort as well as urinary frequency. As many as 12 million people in the U.S. currently suffer from IC. There are few Americans diagnosed with interstitial cystitis that do not know what Elmiron is.
Elmiron treats the symptoms of IC by preventing irritation and swelling of the walls of the bladder. The medicatoin is thought to function as a synthetic mucus layer around the bladder to guard against irritation.
How does Elmiron work to control IC? The mechanism of action of pentosan polysulfate sodium and IC is not fully understood. But, with the caveats expressed below, it does seem to work well for that purpose. Our lawyers do know people (including a lawyer in our office, in fact) who knows of the risk of blindness the Elmiron lawsuits have helped uncover and still take the medication because they simply don't have another path. Elmiron is still the only drug currently approved by the FDA for the treatment of IC-related bladder pain. IC is absolutely awful for many people. (It is hard to know this and support an Elmiron recall instead of just an honest warning. More on that shortly.)
Elmiron was developed and manufactured by Janssen Pharmaceuticals Inc., which is a corporate subsidiary of Johnson & Johnson. Elmiron was first approved by the FDA back in 1996 and since then it has become the standard treatment option for individuals suffering from interstitial cystitis. Elmiron is also sometimes used to treat bladder pain associated with urinary tract infections.
But the question that will be the focus of this litigation is when did Janssen first learn of all the risks and side effects of Elmiron? Janssen may be arguing at trial that it was the last to know. This will be a hard argument to sell, right?
Over 900 Elmiron lawsuits have been filed as of May 2022. More victims are hiring a lawyer. An Elmiron class action MDL was created to rope off these lawsuits 16 months ago. There are many more Elmiron eye injury lawsuits coming in the months ahead.
You should act now if you have an eye injury claim because there are deadlines to sue because of the statute of limitations. But that does not mean you cannot bring an Elmiron lawsuit if your injury occurred some time ago. Most states have a discovery rule which means the statute of limitations does not begin to run until you know or have reason to know how you were injured. Until recently, no one connected the dots between eye injuries and Elmiron.
There is also, parenthetically, some argument from some Elmiron lawyers that this drug is not an efficacious treatment for IC. They point to studies suggesting that Elmiron performs no better than placebo for some IC complications.
This needs to be flushed out. The argument against an Elmiron recall is that this medication is the only path to resolve IC for some patients. But if this argument that Elmiron is not a game changing treatment for IC patients carries water, the risk is hardly worth the benefits and maybe the FDA should consider an Elmiron recall.
Either way, these lawsuits come down to whether Elmiron's side effects require a warning based on the information that was available that communicated the risk of a vision-related injury.Evidence Links Elmiron to Serious Eye Damage
Since its initial release back in 1996, Elmiron has always been viewed as a relatively safe drug with few significant risks or serious side effects. All that has changed very drastically in the last year.
There is strong evidence that Elmiron causes an eye disorder called retinal maculopathy. Long-term exposure appears to increase the risks.
The world began to develop concern about Elmiron’s side effects in 2018 when doctors from the Emory Eye Center in Atlanta, Georgia noticed a strange trend. They had six patients with abnormal damage to the macula region of their eyes and were diagnosed with pigmentary maculopathy.
The doctors eventually realized that all of these patients were long-term users of the drug Elmiron. This led the Emory Eye Center to publish a preliminary report which suggested that Elmiron may be toxic to retinal tissue in the human eye.Further Research Leads to Greater Concern About Elmiron
This warning call immediately prompted a more detailed study into the safety of Elmiron and its potential toxicity to the eyes. This was done by a team of ophthalmologists in Northern California based on thousands of patient records. The alarming results of this research were presented at the annual meeting of the American Academy of Ophthalmology in October 2019.
The study results showed very conclusively that Elmiron was very toxic to the sensitive retina tissue in the back of the eyes. About 25% of patients who used Elmiron displayed signs of maculopathy or significant eye damage.
Many of these victims already have partial or total loss of their vision. When these individuals were examined and tested, doctors found clear signs of drug toxicity related to their prolonged use of Elmiron.
The researchers' data revealed 10 patients with Elmiron-related maculopathy signs. Half of them underwent imaging. The other half underwent fundus examinations. They also found that these 10 patients took Elmiron for an average of 4.2 years with an average cumulative dose of 380g.
The researchers inferred that imaging could detect Elmiron-related maculopathy. Which tells you... Elmiron can cause maculopathy.
Recent studies have linked prolonged use of Elmiron to maculopathy, which is also known as macular retinopathy. Maculopathy is a broad term for any disease or pathologic condition affecting the macula – the central region of the retina in the eye. The type of maculopathy directly associated with Elmiron is called pigmentary maculopathy.
However, macular damage from Elmiron can easily be misdiagnosed as age-related macular degeneration. Maculopathy can result in impairment or even loss of vision.Elmiron Lawsuits for Vision Loss Maculopathy
Hundreds of thousands of people have been exposed to Elmiron: the drug is still on the market.
The recent evidence showing that Elmiron causes serious eye damage is going to lead to a wave of lawsuits against the drug’s manufacturer. If you took Elmiron and were subsequently diagnosed with eye problems involving the retina such as maculopathy the drug maker can be held liable for your injuries.
There is already sufficient evidence establishing a link between Elmiron medication and retinal damage to support a product liability lawsuit. Hundreds and possibly thousands of Elmiron vision loss lawsuits are expected to be filed against Janssen Pharmaceutical.Our Lawyers Are Accepting New Elmiron Eye Damage Lawsuits
Our Elmiron lawyers are taking new Elmiron class action lawsuit cases for victims seeking compensation. We are looking for individuals suffering from side effects who meet the following basic criteria:
- You took Elmiron on a daily for 6-months or longer; and
- After using Elmiron you experienced vision problems and were diagnosed with any of the following conditions:
- Maculopathy/macular retinopathy
- Age-related macular degeneration
- Retinal dystrophy
- Other retinal conditions
If you or a family member meet these criteria, contact our law office today for a free consultation to find out if you qualify for an Elmiron eye injury lawsuit.
Plaintiffs' lawyers are in the discovery phase of the Elmiron eye damage litigation. Trial is set for next year.
Why is the number of claims growing so slowly when our Elmiron lawyers are saying there might be thousands of Elmiron lawsuits?
This is a good question and the answer is important. People are just starting to connect Elmiron to their vision-related injuries. So our attorneys are expecting several thousands of individual Elmiron eye damage lawsuits to get filed eventually. Whether that comes to pass will remain to be seen.
All Elmiron lawsuits in the federal court system are consolidated into an MDL class action.
An MDL is similar to a class action lawsuit. All pending cases from around the country involving a single defective drug or product are consolidated for litigation under a single federal judge for pretrial discovery. So if you file an Elmiron vision loss lawsuit is filed in federal court in California, Texas, New York, Illinois, or any other state, your claim will be transferred to federal court in New Jersey.
Claim details and basic information is gathered and compiled for all of the plaintiffs. Then a few individual “test” cases will be selected for trial and the results of those trials are used to negotiate a global settlement of all the remaining cases. Usually, the settlement has tiers or levels of payments to plaintiffs based on the severity of their injuries.
In addition to Janssen, other defendants in this litigation include Teva, Bayer, Alza, Centocor, Ortho-McNeil, and IVAX.Potential Elmiron Lawsuit Settlement Compensation
It is early in the Elmiron litigation. Our lawyers cannot predict with accuracy what the Elmiron settlement amounts will be. But we can estimate the Elmiron settlement amounts by comparing them to the settlement amounts of similar cases involving similar injuries.
The victims in the Elmiron lawsuits will have the same basic injuries - vision impairment, macular degeneration, and loss of vision. The settlement compensation of vision loss or vision impairment injuries in other cases is a lens to the settlement values in the Elmiron litigation.
Based on this data combined with our own take on this litigation, our Elmiron lawyers anticipate that cases in which the plaintiff suffered total vision loss may see settlement amounts that approach or exceed $1,000,000. The average jury payout in a blindness lawsuit is expected to be much higher, possibly in the $10 million neighborhood.
Is Elmiron settlement talk pure speculation? Of course. Our attorneys keep beating this drum - anything can happen in the litigation, but it is still very early. But you do not need to be a class action lawyer for 25 years to understand that losing your vision is an awful injury that deserves a great deal of compensation if the defendants are culpable.
Elmiron cases involving only vision impairment will likely be grouped into tiers based on the level of impairment to the plaintiff’s vision. The most serious injuries will involve blindness and other permanent vision loss.
Plaintiffs with the most extensive impairment to their vision (maybe 75%-80% impairment) will be in the top settlement tier (“tier 1). Plaintiffs with less impairment (40%-75%) will be in the next tier (“tier 2”) and there will likely be two or more lower settlement compensation tiers after that.
Based on average case values in other vision impairment lawsuits, our Elmiron attorneys guess/believe that an Elmiron eye damage lawsuit in tier 1 may have settlement values in the range of $300,000 to $800,000 per person. Cases in tier 2 may have a settlement amount range somewhere between $75,000 and $250,000 per person. Are these numbers realistic? Our law firm is particularly bullish on the individual average settlement amounts for a meritorious Elmiron lawsuit.
Please keep in mind we are making a lot of assumptions here based on very little information. It is too early to accurately predict the expected settlement amounts of these vision loss lawsuits. But people want to know what the settlement compensation payout could be so we give our unvarnished opinion.Selection of Bellwether Cases in Elmiron Litigation
Millions of Americans take the prescription drug Elmiron (pentosan polysulfate sodium) to treat chronic bladder inflammation and related conditions. In 2018, however, it was discovered that prolonged use of Elmiron can cause vision loss and blindness from a unique type of damage to the retina in the eye.
Since this discovery, over 900 Elmiron lawsuits have been filed in federal court by users of the drug who experienced blindness and vision loss or damage. The Elmiron lawsuits in federal courts have been consolidated into a class-action MDL in New Jersey. The first bellwether test trials in the Elmiron MDL will start in January 2023. At least our attorneys hope so.
Let's review the recent Case Management Order in the Elmiron MDL (CMO No. 17). This CMO lays out the process for the selection of bellwether cases and establishes all of the major discovery and procedural deadlines moving forward.Elmiron MDL Case Management Order No. 17
On October 6, 2021, the judge in the Elmiron MDL (In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation - MDL No. 2973) issued Case Management Order No. 17 ("CMO 17"). CMO 17 is the most significant procedural order to date in the Elmiron MDL because it sets the process for the selection of bellwether cases. CMO 17 also establishes a discovery schedule for those cases selected for bellwether trials.Protocol for Selection of Bellwether Cases
Section III of CMO 17 sets forth detailed protocol and rules for how the parties will go about selecting cases for the bellwether trials set for January 2023. First, the order identifies very simple criteria for what cases are eligible to be bellwether cases. These include standard requirements such as a completed Plaintiff Fact Sheet and documented proof of an Elmiron prescription.
Under CMO 17, an initial pool of 20 cases will be selected as "Bellwether Discovery Cases." 10 of these cases will be selected by the Plaintiffs Executive Committee ("PEC") and 10 will be picked by Lead Counsel for Defendants. CMO 17 requires the parties to notify the judge of their case selections by 11/22/21, so this has presumably already happened.
Once the 20 cases are selected, CMO 17 directs the parties to begin conducting "fact discovery" in the 20 bellwether cases immediately. This means that lawyers in the 20 bellwether cases will be able to conduct normal civil discovery (depositions, requests for documents, etc.) under the federal rules.
To streamline that discovery process, however, CMO 17 imposes certain obligations that each side must comply with. For example, by 12/8/21 each bellwether plaintiff must provide 2 available deposition dates in January 2022. A similar obligation is imposed on defense counsel for their witnesses. CMO 17 further obligates lawyers for both sides to work out a plan for deposing all prescribing and treating doctors in February and March 2022.
Fact discovery in the 20 bellwether cases must be completed by March 31, 2022. Once factual discovery is completed, CMO 17 provides that 3 of the 20 cases will be selected as the Bellwether Trial Cases. One case will be selected by the PEC. One case will be selected by Defendants' Lead Counsel and the Court will select the third case.
Once the three Bellwether Trial Cases are selected, the parties will have the opportunity to conduct expert witness discovery in those cases. CMO 17 lays out clear deadlines for the completion of expert discovery, which will last until September 2022.
- An even newer eye injury mass tort is brewing as Beovu lawsuits are now alleging vision loss
- Taxotere watery eye lawsuits also have a class action MDL in 2022
Section IV of CMO 17 lays out a complete schedule of deadlines for the process of selecting the Bellwether Discovery Cases, completing fact discovery in those cases, and then accomplishing expert discovery in the 3 Bellwether Trial Cases. A list of those deadlines is below:
|11-22-2021||Selection of 20 Bellwether Discovery Cases reported to MDL Judge and Fact Discovery begins in these cases.|
|12-2-2021||Bellwether plaintiffs must provide retinal imaging and ophthalmology treatment records.|
|3-31-2022||Completion of all Fact Discovery.|
|4-8-2022||Selection of 3 initial Bellwether Trial Cases and Expert Discovery begins immediately.|
|5-10-2022||Deadline for Plaintiffs' expert reports in Trial Cases.|
|6-17-2022||Deadline for Defendants' expert reports in Trial Cases.|
|6-27-2022||Deadline for Plaintiff rebuttal expert reports in Trial Cases.|
|9-9-2022||Expert deposition deadline in Trial Cases|
|9-13-2022||Dispositive motions deadline|
|9-30-2022||Daubert motions deadline|
|1-2-2023||1st Bellwether Trial|
|2-1-2023||2nd Bellwether Trial|
|3-1-2023||3rd Bellwether Trial|
- 2021: Kalbag NS, et. al: Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience. Clin Ophthalmol. 2021;15:513-519
- 2020: Doiron, RC, et. al: Possible drug-induced, vision-threatening maculopathy secondary to chronic pentosan polysulfate sodium (Elmiron®) exposure, Can Urol Assoc J. 2020 Feb; 14(2): 10–11, doi: 10.5489/cuaj.6401. This 2020 article, which came out after the Elmiron litigation, summarizes the literature and underscores the risks of newly understood risks of the drug.
- 2019: Jain N, et. al: Association of macular disease with long-term use of pentosan polysulfate sodium: Findings from a U.S. cohort. Br J Ophthalmol. 2019 Nov 6; doi: 10.1136/bjophthalmol-2019-314765
- 2018: Pearce, WA, et. al: Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium, 2018 Nov;125(11):1793-1802. doi: 10.1016. This study found unique pigmentary maculopathy in six patients taking pentosan polysulfate sodium. This is the article that set off alarms in the medical and scientific community we talked about above.
Most Elmiron lawsuits have been filed in (or removed to) federal court and consolidated into the Elmiron MDL.
Recently, a growing number of Elmiron cases are being brought in the state courts in New Jersey. The maker of Elmiron, Janssen Pharmaceuticals, is based in New Jersey so these cases cannot be removed to federal court based on diversity jurisdiction.
This fall, lawyers for a group of 20 Elmiron plaintiffs filed a petition for the consolidation of all Elmiron cases in NJ state courts in a new Multicounty Litigation (MCL). In February 2022, these claims were consolidated under one judge.
This is the state court equivalent of an MDL class. So we will see consolidated pretrial proceedings before a single judge.FAQs: Elmiron Lawsuits
Below are answers to commonly asked questions about the Elmiron eye damage lawsuits.
The use of Elmiron can cause blindness in certain patients. It was recently discovered that extended use of Elmiron can cause a very unique type of eye condition called pigmentary maculopathy that can cause vision impairment and complete blindness.
We spell out the Elmiron lawsuit criteria above. Anyone who has been diagnosed with pigmentary maculopathy after taking the prescription injection drug Elmiron is eligible to bring an Elmiron injury lawsuit. Even if you have not been diagnosed with this specific condition you may still qualify if you took Elmiron and subsequently suffered vision impairment or blindness.
All pending Elmiron suits in federal courts have been consolidated into an MDL, both in federal court and in New Jersey. These lawsuits will undergo a collective process of civil discovery in both jurisdictions. The first Elmiron lawsuit to go to trial will be in January 2023.
So if you file a case in federal court in, for example, California, it will be transferred to New Jersey. Once this discovery phase ends test trials will be held and used to facilitate global settlement discussions.
Elmiron lawsuits could have a very high settlement value because of the serious nature of the injuries. Elmiron plaintiffs with total vision loss could see settlement amounts worth close to $1,000,000. Our lawyers are bullish on these claims. As we discuss above, the amounts will be less for less serious eye damage injuries.
No-Risk in Joining Elmiron Class Action Lawsuit
Again, there are already over 700 Elmiron lawsuits filed MDL against Janssen Pharmaceuticals for failing to warn doctors and patients of the possible vision damage and blindness when using Elmiron for IC. Most lawyers will handle an Elmiron lawsuit on a contingency fee. This means you only pay costs of fees if you receive a settlement compensation payout or a verdict.
Contact Our Law Firm About Elmiron Eye Damage Lawsuits
If you believe your vision was lost or impaired because you used this drug, call our Elmiron attorneys today at 800-553-8082 to discuss your legal options. You can also get a free case evaluation online.